Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
Top Cited Papers
Open Access
- 17 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (14) , 1231-1244
Abstract
Deciding to stop or continue anticoagulation for venous thromboembolism (VTE) after initial treatment is challenging, as individual risks of recurrence and bleeding are heterogeneous. The present study aimed to develop and externally validate models for predicting 5-year risks of recurrence and bleeding in patients with VTE without cancer who completed at least 3 months of initial treatment, which can be used to estimate individual absolute benefits and harms of extended anticoagulation. Competing risk-adjusted models were derived to predict recurrent VTE and clinically relevant bleeding (non-major and major) using 14 readily available patient characteristics. The models were derived from combined individual patient data from the Bleeding Risk Study, Hokusai-VTE, PREFER-VTE, RE-MEDY, and RE-SONATE (n = 15,141, 220 recurrences, 189 bleeding events). External validity was assessed in the Danish VTE cohort, EINSTEIN-CHOICE, GARFIELD-VTE, MEGA, and Tromsø studies (n = 59 257, 2283 recurrences, 3335 bleeding events). Absolute treatment effects were estimated by combining the models with hazard ratios from trials and meta-analyses. External validation in different settings showed agreement between predicted and observed risks up to 5 years, with C-statistics ranging from 0.48–0.71 (recurrence) and 0.61–0.68 (bleeding). In the Danish VTE cohort, 5-year risks ranged from 4% to 19% for recurrent VTE and 1% –19% for bleeding. The VTE-PREDICT risk score can be applied to estimate the effect of extended anticoagulant treatment for individual patients with VTE and to support shared decision-making. BMI, body mass index; DOAC, direct oral anticoagulant; DVT, deep venous thrombosis; Hb, haemoglobin; SBP, systolic blood pressure; VKA, vitamin K antagonist; VTE, venous thromboembolism.Keywords
Funding Information
- Netherlands Organization for Health Research and Development (848018012)
This publication has 29 references indexed in Scilit:
- Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case–control studyJournal of Thrombosis and Haemostasis, 2014
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- Shared Decision Making to Improve Care and Reduce CostsNew England Journal of Medicine, 2013
- Estimating treatment effects for individual patients based on the results of randomised clinical trialsBMJ, 2011
- Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trialsBMJ, 2011
- Cohort profile: The Tromso StudyInternational Journal of Epidemiology, 2011
- Use and Misuse of the Receiver Operating Characteristic Curve in Risk PredictionCirculation, 2007
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Malignancies, Prothrombotic Mutations, and the Risk of Venous ThrombosisJAMA, 2005